- Noema Pharma AG, a Basel, Switzerland-based clinical-stage company targeting orphan neurological disorders, raised a Series A financing round, raising CHF54m ($59m USD)
- The round co-led by Sofinnova Partners and Polaris Partners with participation from new international investors Gilde Healthcare, Invus, and BioMed Partners
- The company also intends to use the funds to further develop its clinical-stage pipeline
- The product candidates will also develop in neurological indications with severe unmet need
- Noema Pharma is a company targeting orphan neurological disorders characterized by imbalanced neuronal networks
- The company developing four mid-clinical-stage therapeutic products in-licensed from Roche and with strong safety packages
